[4]Saura C, Modi S, Ian Krop I,et al.Trastuzumab Deruxtecan (T-DXd)in Patients with HER2-Positive Metastatic Breast Cancer: Updated Survival Results from a Phase 2 Trial (DESTINY-Breast01).2021 ESMO. 279P. [5]André F, Park Y H, Kim S B, et al. Trastuzumab deruxtecan versus tr...
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020 Aug;182(3):689-697. Jordan, Nicole Vincent et ...
[7] Pernas S, Tolaney SM. Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat. 2022 Apr 9. [8] Larionov AA. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive ...
P. (2021). Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology.JCO-20.
[1] Bachelot T, Romieu G, Campone et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub...
Jackisch C ( 2006 ). HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy . Oncologist 11 (Suppl. 1 ): 34 – 41 .Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. The Oncologist . 2006; 11 (suppl 1):34–41....
[7] Pernas S, Tolaney SM. Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat. 2022 Apr 9. [8] Larionov AA. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Front Oncol. 2018 Apr 3;8:89...
参考来源: [1]practiceupdate.com/expe [2] Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Eng J Med. 2020;382(7):597-609. doi:10.1056/NEJMoa1914609 [3] oncologypro.esmo.org/me ...
1. YanM, BianL, HuX, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1:13. ...
[9].Blumenthal GM, Scher NS, Cortazar P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res. 2013;19(18):4911-4916. ...